This document represents the summary of type 2 diabetes management proposed by the American Association of Clinical Endocrinology and the American College of Endocrinology. According to this paper, the risk of hypoglycemia with GLP-1 receptor agonists is low, and they reduce fluctuations in both fasting and postprandial glucose levels. No dose adjustment is required for semaglutide in chronic kidney disease, but monitoring is recommended. This evidence concerns the gene GLP1R and Hypoglycemia.